Table 4.
CEC Association Results (N=5293) for Variants Previously Associated With Blood Lipid Levels or CAD Risk
| SNP | Chromosome (Position) | CEC | Allele A1/A2 | EAF | Model 1 | Model 2 (Adjusted for HDL‐C and Triglycerides) | Locus (Lipid Traits and CAD) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| β | SE | P Value | β | SE | P Value | ||||||
| rs12678919 | 8 (19 844 222) | J774 basal | A/G | 0.092 | 0.1975 | 0.0337 | 4.447×10−9* | 0.073 | 0.034 | 0.03163 | LPL (HDL‐C, triglycerides, CAD) |
| rs1532085 | 15 (58 683 366) | A/G | 0.386 | −0.1176 | 0.0203 | 7.026×10−9* | −0.0494 | 0.0204 | 0.01562 | LIPC (TC, HDL‐C, triglycerides) | |
| rs3764261 | 16 (56 993 324) | A/C | 0.685 | −0.145 | 0.0211 | 6.565×10−12* | 0.0283 | 0.0211 | 0.1798 | CETP (TC, HDL‐C, LDL‐C, triglycerides) | |
| rs1260326 | 2 (27 730 940) | J774 stimulated | T/C | 0.387 | −0.0838 | 0.0217 | 0.0001079* | −0.0512 | 0.022 | 0.02011 | GCKR (TC, triglycerides) |
| rs964184 | 11 (116 648 917) | C/G | 0.857 | 0.1143 | 0.0286 | 6.336×10−5* | 0.0593 | 0.0295 | 0.04428 | APOA1/C3/A4/A5 (TC, HDL‐C, LDL‐C, triglycerides, CAD) | |
| rs3764261 | 16 (56 993 324) | A/C | 0.685 | −0.1301 | 0.0209 | 4.932×10−10* | 0.0201 | 0.0211 | 0.3389 | CETP (TC, HDL‐C, LDL‐C, triglycerides) | |
| rs7412 | 19 (45 412 079) | T/C | 0.917 | −0.214 | 0.0353 | 1.285×10−9* | −0.1616 | 0.0357 | 6.084×10−6* | APOE/C1/C2/C4 (TC, HDL‐C, LDL‐C, CAD) | |
| rs4253772 | 22 (46 627 603) | T/C | 0.886 | −0.1214 | 0.0307 | 7.491×10−5* | −0.0927 | 0.031 | 0.002815 | PPARA (TC, LDL‐C) | |
| rs1260326 | 2 (27 730 940) | J774 ABCA1 dependent | T/C | 0.387 | −0.0989 | 0.0218 | 5621×10−6* | −0.0495 | 0.022 | 0.0244 | GCKR (TC, triglycerides) |
| rs2954029 | 8 (126 490 972) | A/T | 0.453 | −0.0803 | 0.0193 | 3.288×10−5* | −0.0604 | 0.0196 | 0.002046 | TRIB1 (TC, HDL‐C, LDL‐C, triglycerides, CAD) | |
| rs964184 | 11 (116 648 917) | C/G | 0.857 | 0.2019 | 0.0281 | 6.781×10−13* | 0.0756 | 0.0287 | 0.008398 | APOA1/C3/A4/A5 (TC, HDL‐C, LDL‐C, triglycerides, CAD) | |
| rs7412 | 19 (45 412 079) | T/C | 0.917 | −0.2301 | 0.035 | 4.882×10−11* | −0.1571 | 0.0357 | 1.066×10−5* | APOE/C1/C2/C4 (TC, HDL‐C, LDL‐C, CAD) | |
| rs964184 | 11 (116 648 917) | BHK stimulated | C/G | 0.857 | 0.1169 | 0.0284 | 3.793×10−5* | 0.0435 | 0.0291 | 0.1344 | APOA1/C3/A4/A5 (TC, HDL‐C, LDL‐C, triglycerides, CAD) |
| rs3764261 | 16 (56 993 324) | A/C | 0.685 | −0.1149 | 0.0211 | 5.381×10−8* | 0.0254 | 0.0212 | 0.2302 | CETP (TC, HDL‐C, LDL‐C, triglycerides) | |
| rs7412 | 19 (45 412 079) | T/C | 0.917 | −0.236 | 0.0351 | 1.745×10−11* | −0.1872 | 0.0353 | 1.178×10−7* | APOE/C1/C2/C4 (TC, HDL‐C, LDL‐C, CAD) | |
| rs6065906 | 20 (44 554 015) | T/C | 0.215 | −0.0654 | 0.0238 | 0.005993 | −0.0886 | 0.0239 | 0.0002143* | PLTP (HDL‐C, triglycerides) | |
For these analyses, the statistical threshold is α=2.1×10−4 (Methods). * indicates significant P values. Coordinates are for build hg19 of the human genome. Alleles are on the positive strand. The EAF and the direction of the effect size (β) are for allele A2. Model 1 is adjusted for sex, age squared, CAD status, experimental batches, statin treatment, and the first 10 principal components. Model 2 includes the same covariates as model 1, but also HDL‐C and triglyceride levels. BHK indicates baby hamster kidney; CAD, coronary artery disease; CEC, cholesterol efflux capacity; EAF, effect allele frequency; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SNP, single‐nucleotide polymorphism; TC, total cholesterol.